Drugs

, Volume 64, Issue 15, pp 1671–1682

A Review of Ipratropium Bromide/Fenoterol Hydrobromide (Berodual®) Delivered Via Respimat® Soft Mist™ Inhaler in Patients with Asthma and Chronic Obstructive Pulmonary Disease

  • Frank Kässner
  • Rick Hodder
  • Eric D. Bateman
Review Article

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) can be effectively treated by the use of bronchodilator therapies delivered by inhalation. Berodual® is a fixed combination of the anticholinergic agent ipratropium bromide (IB) and the β2-adrenergic agonist fenoterol hydrobromide (FEN). IB/FEN has been available for the treatment of asthma and COPD in a pressurised metered dose inhaler (MDI) [pMDI] formulation for many years.

The pMDI is the most widely used device for the delivery of inhaled medications, such as IB/FEN. However, most conventional pMDIs contain chlorofluoro-carbon (CFC) propellants, which are currently being withdrawn because of their detrimental effects on the environment. This has resulted in alternative methods of drug delivery being developed. Respimat® Soft Mist™ Inhaler (SMI) is a new generation, propellant-free inhaler that generates a fine, slow-moving cloud (the Soft Mist™) which can be easily inhaled. Scintigraphic studies have shown that this improves deposition of drugs in the lung and results in less oropharyngeal deposition than the CFC-MDI.

A clinical development programme has been conducted to compare the efficacy and safety of IB/FEN delivered via Respimat® SMI with that of IB/FEN via CFC-MDI in the treatment of patients with asthma or COPD. Five clinical studies (two phase II and three phase III) investigated dosages of IB/FEN 5/12.5μg to 320/800μg via Respimat® SMI in single and multiple dose administration regimens. Four of the trials were conducted in patients with asthma (three in adults and one in children), while one phase III trial was conducted in patients with COPD. In phase III, 2058 patients participated, with a total of 1112 patients treated with IB/FEN via Respimat® SMI. In the phase III studies, each dose from Respimat® SMI was given in one actuation compared with two actuations with the CFC-MDI. In the paediatric asthma phase III study, all CFC-MDI doses were delivered via a spacer device.

The results of the trials demonstrated that IB/FEN via Respimat® SMI allows a reduction in the nominal dose of IB/FEN, while offering similar therapeutic efficacy and safety to a CFC-MDI. In children, Respimat® SMI obviates the need for a spacer.

References

  1. 1.
    Nicklas RA. National and international guidelines for the diagnosis and treatment of asthma. Curr Opin Pulm Med 1997; 3: 51–5PubMedCrossRefGoogle Scholar
  2. 2.
    British Thoracic Society, National Asthma Campaign, Royal College of Physicians of London. The British guidelines on asthma management. Thorax 1997; 52: S1–21CrossRefGoogle Scholar
  3. 3.
    American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77–121Google Scholar
  4. 4.
    National Institutes of Health; National Heart, Lung and Blood Institute. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Report of NHLBI/WHO Workshop, April1998. Updated 2003 [online]. Available from URL: http://www.goldcopd.com [Accessed 2004 Mar 1]
  5. 5.
    National Institutes of Health. Global Initiative for Asthma. Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report. Bethesda (MD): National Institutes of Health, National Heart Lung and Blood Institute; 2002 Apr. Publication no.: 02-3659Google Scholar
  6. 6.
    Pavia D. Efficacy and safety of inhalation therapy in chronic obstructive pulmonary disease and asthma. Respirology 1997; 2 Suppl. 1: S5–10PubMedGoogle Scholar
  7. 7.
    Newman SP, Brown J, Steed KP, et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines. Chest 1998; 113: 957–63PubMedCrossRefGoogle Scholar
  8. 8.
    Kunkel G, Magnussen H, Bergmann KC, et al. Respimat® (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients. Respiration 2000; 67: 306–14PubMedCrossRefGoogle Scholar
  9. 9.
    Ganderton D. Targeted delivery of inhaled drugs: current challenges and future goals. J Aerosol Med 1999; 12 Suppl. 1: S3–8PubMedGoogle Scholar
  10. 10.
    Lötvall J, O’Byrne P. Targeting drugs to the airways by different inhalation devices. Biodrugs 1999; 12: 279–89PubMedCrossRefGoogle Scholar
  11. 11.
    Goldberg J, Freund E, Beckers B, et al. Improved delivery of fenoterol plus ipratropium bromide using Respimat® compared with a conventional metered dose inhaler. Eur Respir J 2001; 17: 225–32PubMedCrossRefGoogle Scholar
  12. 12.
    Vincken W, Bantje T, Middle MV, et al. Long-term efficacy and safety of ipratropium bromide plus fenoterol via Respimat® Soft Mist® Inhaler (SMI) versus a pressurised metered dose inhaler in asthma. Clin Drug Invest 2004; 24(1): 17–28CrossRefGoogle Scholar
  13. 13.
    von Berg A, Jeena PM, Soemantri PA, et al. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat® Soft Mist™ Inhaler vs a conventional metered dose inhaler plus spacer in children with asthma. Pediatr Pulmonol 2004; 37: 264–72CrossRefGoogle Scholar
  14. 14.
    Kilfeather SA, Ponitz HH, Beck E, et al. Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft Mist™ Inhaler in patients with COPD. Respir Med 2004; 98: 387–97PubMedCrossRefGoogle Scholar
  15. 15.
    Hodder R, Pavia DD, Dewberry HM, et al. Comparison of the safety relating to paradoxical bronchoconstriction of ipratropium bromide (IB) alone or combined with fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (CFC-MDI) in asthma and COPD patients [abstract]. Eur Respir J 2002; 20 Suppl. 38: 246sGoogle Scholar
  16. 16.
    Traunecker W, Muacevic G. Pharmacological effects of a combination of fenoterol hydrobromide and ipratropium bromide. Respiration 1986; 50(4): 244–51PubMedCrossRefGoogle Scholar
  17. 17.
    Molkenboer JFWM, Cornelissen PJG. A double-blind randomised cross-over study assessing the efficacy of Berodual in comparison to its components ipratropium bromide and fenoterol in chronic bronchitis. Postgrad J Med 1987; 64: 19a-20aGoogle Scholar
  18. 18.
    O’Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease. Can Respir J 2003; 10: Suppl. A: 11A–65APubMedGoogle Scholar
  19. 19.
    Frolund L, Madsen F, Svendsen UG, et al. Comparison of two aerosols containing both fenoterol and ipratropium in a high (Duovent®) and low (Berodual®) concentration, respectively. Respiration 1986; 50 Suppl. 2: 270–3Google Scholar
  20. 20.
    Philip-Joet F, Reynaud-Gaubert M, Jirou-Najou JL, et al. Comparison of Berodual® and salbutamol in asthma: a multicenter evaluation. Respiration 1990; 57: 379–83PubMedCrossRefGoogle Scholar
  21. 21.
    Jedrys U, Kurzawa R, Haluszka J, et al. Evaluation of the bronchodilatory activity of Berodual® and its components: fenoterol and ipratropium bromide in children with bronchial asthma [in Polish]. Pneumonol Alergol Pol 1994; 62: 615–22PubMedGoogle Scholar
  22. 22.
    Baculard A. Role of Bronchodual in the long-term treatment of asthma in children [in French]. Arch Pediatr 1995; 2 Suppl. 2: S149–53CrossRefGoogle Scholar
  23. 23.
    Ciappi G, Magnini P, Valente S, et al. Dose-response relationship: fenoterol, ipratropium bromide and their combination. Respiration 1986; 50 Suppl. 2: 140–3CrossRefGoogle Scholar
  24. 24.
    Serra C, Giacopelli A, Luciani G. Acute controlled study of the dose-response relationship of fenoterol, ipratropium bromide and their combination. Respiration 1986; 50 Suppl. 2: 144–7CrossRefGoogle Scholar
  25. 25.
    Duerden M, Price D. Training issues in the use of inhalers. Dis Manag Health Outcomes 2001; 9: 75–87CrossRefGoogle Scholar
  26. 26.
    Erickson SR, Horton A, Kirking DM. Assessing metered-dose inhaler technique: comparison of observation vs patient self-report. J Asthma 1998; 35: 575–83PubMedCrossRefGoogle Scholar
  27. 27.
    Larsen JS, Hahn M, Kockevar JW, et al. Administration errors with a conventional metered dose inhaler versus a novel breath actuated device. Ann Allergy 1993; 71: 103–6PubMedGoogle Scholar
  28. 28.
    Zierenberg B, Eicher J, Dunne S, Freund B. Boehringer Ingelheim nebulizer BINEB®: a new approach to inhalation therapy. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory Drug Delivery V. Buffalo Grove (IL): Interpharm Press, 1996: 187–93Google Scholar
  29. 29.
    Zierenberg B. Optimizing the in vitro performance of the Respimat®. J Aerosol Med 1999; 12 Suppl. 1: S19–24PubMedCrossRefGoogle Scholar
  30. 30.
    Spallek M, Hochrainer D, Wachtel H. Optimizing nozzles for soft mist inhalers. Respiratory Drug Delivery VIII 2002; 2: 375–8Google Scholar
  31. 31.
    Newman SP, Steed KP, Reader SJ, et al. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebuliser. J Pharm Sci 1996; 85: 960–4PubMedCrossRefGoogle Scholar
  32. 32.
    Steed KP, Towse LJ, Freund B, et al. Lung and oropharyngeal depositions of fenoterol hydrobromide delivered from the prototype III hand-held multidose Respimat® nebuliser. Eur J Pharm Sci 1997; 5: 55–61CrossRefGoogle Scholar
  33. 33.
    Littner M, Taylor JR, Ghafouri M, et al. A dose ranging study of ipratropium bromide solution delivered via a novel soft mist inhaler in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 2000; 16 Suppl. 31: 55SGoogle Scholar
  34. 34.
    van Noord JA, Smeets JJ, Creemers JPHM, et al. Delivery of fenoterol via Respimat®, a novel ‘soft mist’ inhaler: a randomised, double-blind (within device), placebo-controlled, crossover, dose-ranging study in asthmatic patients. Respiration 2000; 67: 672–8PubMedCrossRefGoogle Scholar
  35. 35.
    Maesen FPV, Greefhorst LPM, Smeets JJ, et al. Therapeutic equivalence of a novel HFA134a-containing metered-dose inhaler and the conventional CFC inhaler (Berodual®) for the delivery of a fixed combination of fenoterol/ ipratropium bromide. Respiration 1997; 64: 273–80PubMedCrossRefGoogle Scholar
  36. 36.
    Morrison JFJ, Jones PC, Muers MF. Assessing physiological benefit from domiciliary nebulized bronchodilators in severe airflow limitation. Eur Respir J 1992; 5: 424–9PubMedGoogle Scholar

Copyright information

© Adis data information BV 2004

Authors and Affiliations

  • Frank Kässner
    • 1
  • Rick Hodder
    • 2
  • Eric D. Bateman
    • 3
  1. 1.Pneumologisches Zentrum CottbusGroβGermany
  2. 2.Divisions of Pulmonary and Critical Care MedicineUniversity of OttawaOttawaCanada
  3. 3.UCT Lung InstituteUniversity of Cape TownCape TownSouth Africa
  4. 4.Zentrum für Pneumologie und SchlafmedizinCottbusGermany

Personalised recommendations